Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, single blind, comparative, three way crossover clinical study to evaluate the efficacy and safety of a novel nasal spray (FDC of Azelastine hydrochloride and Mometasone furoate monohydrate) compared to its individual components Azelastine hydrochloride 137 mcg and Mometasone furoate monohydrate 50 mcg nasal sprays in patients suffering from perennial Allergic Rhinitis.

Trial Profile

A randomized, single blind, comparative, three way crossover clinical study to evaluate the efficacy and safety of a novel nasal spray (FDC of Azelastine hydrochloride and Mometasone furoate monohydrate) compared to its individual components Azelastine hydrochloride 137 mcg and Mometasone furoate monohydrate 50 mcg nasal sprays in patients suffering from perennial Allergic Rhinitis.

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Mar 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azelastine/mometasone (Primary) ; Azelastine; Mometasone
  • Indications Perennial allergic rhinitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Cipla
  • Most Recent Events

    • 19 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top